154 related articles for article (PubMed ID: 36369706)
1. Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data.
Tornesello ML; Tornesello AL; Starita N; Cerasuolo A; Izzo F; Buonaguro L; Buonaguro FM
Expert Opin Ther Targets; 2022 Sep; 26(9):767-780. PubMed ID: 36369706
[TBL] [Abstract][Full Text] [Related]
2. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
Ningarhari M; Caruso S; Hirsch TZ; Bayard Q; Franconi A; Védie AL; Noblet B; Blanc JF; Amaddeo G; Ganne N; Ziol M; Paradis V; Guettier C; Calderaro J; Morcrette G; Kim Y; MacLeod AR; Nault JC; Rebouissou S; Zucman-Rossi J
J Hepatol; 2021 May; 74(5):1155-1166. PubMed ID: 33338512
[TBL] [Abstract][Full Text] [Related]
3. The role of telomeres and telomerase in cirrhosis and liver cancer.
Nault JC; Ningarhari M; Rebouissou S; Zucman-Rossi J
Nat Rev Gastroenterol Hepatol; 2019 Sep; 16(9):544-558. PubMed ID: 31253940
[TBL] [Abstract][Full Text] [Related]
4. Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.
Yang X; Guo X; Chen Y; Chen G; Ma Y; Huang K; Zhang Y; Zhao Q; Winkler CA; An P; Lyu J
Oncotarget; 2016 May; 7(19):27838-47. PubMed ID: 27056898
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B Virus-Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma.
Sze KM; Ho DW; Chiu YT; Tsui YM; Chan LK; Lee JM; Chok KS; Chan AC; Tang CN; Tang VW; Lo IL; Yau DT; Cheung TT; Ng IO
Hepatology; 2021 Jan; 73(1):23-40. PubMed ID: 32170761
[TBL] [Abstract][Full Text] [Related]
6. Telomere biology and telomerase mutations in cirrhotic patients with hepatocellular carcinoma.
Donaires FS; Scatena NF; Alves-Paiva RM; Podlevsky JD; Logeswaran D; Santana BA; Teixeira AC; Chen JJ; Calado RT; Martinelli ALC
PLoS One; 2017; 12(8):e0183287. PubMed ID: 28813500
[TBL] [Abstract][Full Text] [Related]
7. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
8. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.
Ko E; Seo HW; Jung ES; Kim BH; Jung G
Oncotarget; 2016 Jan; 7(1):684-99. PubMed ID: 26575952
[TBL] [Abstract][Full Text] [Related]
9. Promoter mutations and cellular distribution of telomerase in non-clear cell and clear cell hepatocellular carcinoma.
Huang W; Zhou W; Li C; Yang Y; Shang YK; Chen C; Zhang J; Yao R; Wang P; Wen W; Liu HQ; Wang L; Li X; Bian H; Chen ZN
Oncotarget; 2017 Apr; 8(16):26288-26297. PubMed ID: 28460432
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma.
Lee HW; Park TI; Jang SY; Park SY; Park WJ; Jung SJ; Lee JH
Medicine (Baltimore); 2017 Feb; 96(5):e5766. PubMed ID: 28151853
[TBL] [Abstract][Full Text] [Related]
11. Suppression of PROX1-mediated TERT expression in hepatitis B viral hepatocellular carcinoma.
Kim YJ; Yoo JE; Jeon Y; Chong JU; Choi GH; Song DG; Jung SH; Oh BK; Park YN
Int J Cancer; 2018 Dec; 143(12):3155-3168. PubMed ID: 29987895
[TBL] [Abstract][Full Text] [Related]
12. Telomerase reverse transcriptase regulates DNMT3B expression/aberrant DNA methylation phenotype and AKT activation in hepatocellular carcinoma.
Yu J; Yuan X; Sjöholm L; Liu T; Kong F; Ekström TJ; Björkholm M; Xu D
Cancer Lett; 2018 Oct; 434():33-41. PubMed ID: 30017965
[TBL] [Abstract][Full Text] [Related]
13. Identification of genes involved in the regulation of TERT in hepatocellular carcinoma.
Amisaki M; Tsuchiya H; Sakabe T; Fujiwara Y; Shiota G
Cancer Sci; 2019 Feb; 110(2):550-560. PubMed ID: 30447097
[TBL] [Abstract][Full Text] [Related]
14. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.
Nault JC; Calderaro J; Di Tommaso L; Balabaud C; Zafrani ES; Bioulac-Sage P; Roncalli M; Zucman-Rossi J
Hepatology; 2014 Dec; 60(6):1983-92. PubMed ID: 25123086
[TBL] [Abstract][Full Text] [Related]
15. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.
Pezzuto F; Izzo F; Buonaguro L; Annunziata C; Tatangelo F; Botti G; Buonaguro FM; Tornesello ML
Oncotarget; 2016 Aug; 7(34):54253-54262. PubMed ID: 27276713
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.
Yuan X; Larsson C; Xu D
Oncogene; 2019 Aug; 38(34):6172-6183. PubMed ID: 31285550
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
[TBL] [Abstract][Full Text] [Related]
18. HCV Induces Telomerase Reverse Transcriptase, Increases Its Catalytic Activity, and Promotes Caspase Degradation in Infected Human Hepatocytes.
Zhu Z; Tran H; Mathahs MM; Moninger TO; Schmidt WN
PLoS One; 2017; 12(1):e0166853. PubMed ID: 28056029
[TBL] [Abstract][Full Text] [Related]
19. Positive association of long telomeres with the invasive capacity of hepatocellular carcinoma cells.
Ko E; Jung G
Biochem Biophys Res Commun; 2014 May; 447(2):358-63. PubMed ID: 24732358
[TBL] [Abstract][Full Text] [Related]
20. The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma.
Yuan X; Cheng G; Yu J; Zheng S; Sun C; Sun Q; Li K; Lin Z; Liu T; Li P; Xu Y; Kong F; Bjorkholm M; Xu D
Oncotarget; 2017 Apr; 8(14):23120-23129. PubMed ID: 28416747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
